title: Prevention of leukocyte migration inhibitory factor activity by glucagon.
abstract: Leukocyte migration inhibitory factor (LMIF) activity was tested before and after glucagon administration both in vivo and in vitro. In vivo glucagon 1 mg i.v. vs saline administration inhibited LMIF production by T lymphocytes in 85.21% patients (p less than 0.01). In vitro glucagon in physiologic (125 pg/ml) and pharmacologic (50 ng/ml) doses increased the migration area vs PPD 250 microL (migration index 0.5127 vs 0.3210; p less than 0.05). These results show a significant inhibitory effect of glucagon upon LMIF activity. We suggest that glucagon acts by enhancement of the intralymphocytic cAMP/cGMP ratio (cyclic adenosine monophosphate/cyclic guanosine monophosphate).
authors.forename: D
authors.initials: D
authors.lastname: Pereţianu
authors.forename: A
authors.initials: A
authors.lastname: Deleanu
authors.forename: V
authors.initials: V
authors.lastname: Lotreanu
authors.forename: A
authors.initials: A
authors.lastname: Mogoş
authors.forename: C
authors.initials: C
authors.lastname: Beşliu
authors.forename: D
authors.initials: D
authors.lastname: Tănase
mesh_terms: D000328:Adult; D000368:Aged; D000242:Cyclic AMP / Q000032:analysis; D006152:Cyclic GMP / Q000032:analysis; D005260:Female; D005934:Glucagon / Q000494:pharmacology*; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007961:Leukocyte Migration-Inhibitory Factors / Q000037:antagonists & inhibitors*; D008214:Lymphocytes / Q000032:analysis; D008222:Lymphokines / Q000037:antagonists & inhibitors*; D008297:Male; D008875:Middle Aged
chemical_list: D007961:Leukocyte Migration-Inhibitory Factors; D008222:Lymphokines; D005934:Glucagon; D000242:Cyclic AMP; D006152:Cyclic GMP